Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 12/20 | 0.52 |
| ▸ | HTR2C | P28335 | 12/20 | 0.52 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120729 | 0.84 | KIF11 (0.60) | KIF11SIRT1MAPKAPK2SIRT2 | |
| SCHEMBL1120636 | 0.83 | KIF11 (0.60) | KIF11SIRT1HTR2AHTR2CHTR2B | |
| SCHEMBL21732153 | 0.82 | KIF11 (0.56) | KIF11SIRT1HTR2AHTR2CSIRT2 | |
| SCHEMBL3720921 | 0.78 | MCHR1 (0.51) | KIF11SIRT1HTR2AHTR2C | |
| SCHEMBL13049423 | 0.77 | KIF11 (0.66) | KIF11HTR2AHTR2CMAPKAPK2HTR2B | |
| SCHEMBL7676744 | 0.77 | KIF11 (0.54) | KIF11SIRT1MAPKAPK2SIRT2SIRT3 | |
| SCHEMBL7680175 | 0.77 | KIF11 (0.54) | KIF11SIRT1MAPKAPK2SIRT2SIRT3 | |
| SCHEMBL7677808 | 0.76 | SIRT1 (0.55) | KIF11SIRT1SIRT2SIRT3 | |
| SCHEMBL7852925 | 0.76 | KIF11 (0.53) | KIF11SIRT1MAPKAPK2SIRT2SIRT3 | |
| SCHEMBL7851681 | 0.75 | SIRT1 (0.54) | KIF11SIRT1SIRT2SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9260429-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184306-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130137705-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-05-30 | — | — | US | disclosed |
| US-20130131077-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130123277-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8338447-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2480079-A1 | PYRIDO(3,4-B)INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011038162-A1 | PYRIDO(3,4-B)INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| EP-2280968-A2 | PYRIDO [3, 4-B]INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009120717-A2 | PYRIDO [3, 4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184306-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | KIF11 3101/4885SIRT1 3213/4885HTR2A 12/4885 |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | KIF11 3101/4885SIRT1 3213/4885HTR2A 12/4885 |
| US-20130123277-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR2C, HTR4 | KIF11 3164/4885SIRT1 3159/4885HTR2A 12/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | KIF11 3101/4885SIRT1 3213/4885HTR2A 12/4885 |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | KIF11 3101/4885SIRT1 3213/4885HTR2A 12/4885 |
| US-20130131077-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR2C, HTR4 | KIF11 3055/4885SIRT1 3189/4885HTR2A 12/4885 |
| US-20130137705-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | KIF11 3101/4885SIRT1 3213/4885HTR2A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.